TransMedics Group Inc vs Uber Technologies Inc — how do they compare? TransMedics Group Inc trades at $79.33 (market cap $2.81B), while Uber Technologies Inc trades at $70.36 (market cap $139.81B). The key difference: Uber Technologies Inc is far larger — about 49.8× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (962,415 versus 11,879,194). Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Uber Technologies Inc for 88 Days on average.
| TMDX | UBER | |
|---|---|---|
Market Cap | $2.81B | $139.81B |
Volume | 962,415 | 11,879,194 |
Sector | Health | Technology |
52-Week High | $150.42 | $99.72 |
52-Week Low | $61.99 | $65.94 |
Typical Hold Time | 24 Days | 88 Days |
Enterprise Value | $3.21B | $149.15B |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Uber (UBER) trades at $70.24, up 1.68% on the day, with a bearish technical signal from moving averages but strong fundamentals including 2025 revenue of $52.02 billion and net income of $10.05 billion. The company has beaten EPS estimates in two of the last three quarters and expanded its Uber Eats partnership with Costco to 47 states as of September 16, 2026. Operating cash flow grew to $10.10 billion in 2025, supporting a robust balance sheet with $6.98 billion in cash.
The outlook is positive given analyst consensus of a $104.72 price target and 82.54% buy ratings, though risks include a projected negative net cash flow in 2026 and competitive pressures from autonomous vehicle entrants. Upside is driven by earnings momentum and strategic expansions, while investor caution is warranted on execution and capital expenditure trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →